Leading Research Team Highlights Role Of SphygmoCor®

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor® system for advanced hypertension management, announced today that a new presentation by the Harvard-MIT Edelman Laboratories' Eyal Ben Assa MD and Elazer Edelman, MD, PhD has highlighted the importance of central blood pressure assessment, as performed by the SphygmoCor system.

Itasca, IL (PRWEB) - AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor® system for advanced hypertension management, announced today that a new presentation by the Harvard-MIT Edelman Laboratories' Eyal Ben Assa MD and Elazer Edelman, MD, PhD has highlighted the importance of central blood pressure assessment, as performed by the SphygmoCor system.

Dr. Edelman is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT, Professor of Medicine at Harvard Medical School, and Senior Attending Physician in the coronary care unit at the Brigham and Women's Hospital in Boston. He directs the Harvard-MIT Biomedical Engineering Center. The presentation “The Role of Non-invasive Central Aortic Pressures in Cardiovascular Disease,” at the Cardiovascular Research Foundation's Transcatheter Cardiovascular Therapeutics conference in Washington, DC highlighted the clinical value of non-invasively measuring the central aortic blood pressure waveform for cardiovascular disease management, particularly in heart failure prediction and treatment, noting that central pressure contributes to better patient evaluation and non-invasive measurements were easy to perform and were well validated.

Dr Edelman said: “Non-invasive central pressure waveform analysis provides important physiological information to inform and optimize patient management across a broad spectrum of therapeutic areas. Our research using the SphygmoCor system is designed to inform and expand the clinical potential of this technology beyond its current clinical use in advanced hypertension management.”

Duncan Ross, CEO of AtCor Medical said: “We are pleased with this recognition from a researcher internationally acknowledged for his work bringing cardiovascular translational research to an international level of excellence. It is estimated that in the US alone, US$32 billion is spent treating heart failure including direct and indirect costs. As healthcare models shift to preventive, individualized medicine, AtCor Medical is committed to providing clinical solutions which enable physicians to provide targeted treatment for their patients’ unique vascular physiologies. We are delighted to partner with Dr. Edelman, one of the world’s leading medical device clinical investigators, and his team to enable improved care for thousands of patients around the world.”

About AtCor Medical
AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company’s SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements. SphygmoCor is essential for hypertension management.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States and Europe. For further information, visit http://www.atcormedical.com.